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Abstract
Background: High blood lipoprotein concentrations are one of the major risk factors for cardiovascular diseases.
Drug therapy is the base of treatment; statins in particular. Both brand-name and generic presentations are available for
statin therapy of high cholesterol levels. Factors that may influence their use in routine medical practice include, among
others, patient persistence and adherence to treatment as prescribed by physicians. The aim of this retrospective analysis
was to provide real-world evidence of treatment persistence and adherence and their consequences on economic and
patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain.
Methods: Existing real-world electronic medical records abstracted from a database of two regions in Spain were
analyzed. The analysis compared generic versus brand-name statins data from subjects’ who started treatment
between July 1, 2010 and June 30, 2012. Treatment persistence, adherence expressed as medication possession ratio
(MPR), healthcare resource utilization and their costs were analyzed together with patient’s at-goal rates of low-density-
lipoprotein-cholesterol (LDL-c), incidence of any major cardiovascular event (CVE) and all-cause mortality during a 5-year
follow-up period. Multivariate analyses were applied.
Results: A total of 13,244 records were included. Persistence was lower with generics; adjusted hazard ratio -HR- [95%
confidence interval]: 0.86 [0.82–0.91], p < 0.001) and MPR was also lower: 61.5% vs. 65.1% (p < 0.001). Less patients with
generics reached their LDL-c goal: 39.2% [38.3–40.2%] vs. 42.0% [40.2–43.7%]; adjusted odds ratio; 0.87 [0.80–0.95],
p = 0.003. Compared to brand-name statins, the observed probability of occurrence of a CVE; HR: 1.31 [1.15–1.50],
p < 0.001, and also all-cause deaths; HR: 1.36 [1.15–1.62], was significantly higher with generics; p < 0.001 in both
cases. Adjusted mean total healthcare cost per patient was also higher with generic than with brand-name
statins: €9118 (9059–9176) vs. €7980 (7853–8808) [adjusted difference: €1137 (997–1277), p < 0.001].
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Conclusion: This retrospective cost-consequences analysis found poorer treatment persistence and adherence in
patients who first started therapy with generic instead of brand-name statins in routine medical practice in Spain.
Also, patients receiving generics were more unlikely to reach LDL-c goals, showed increased probability of having
CVE and all-cause mortality at a higher cost to payers.
Keywords: Hypercholesterolemia, Adherence, Persistence, Costs, Outcomes, patient’s at goal, Cardiovascular
events, Generics, Brand-name
Background
Cardiovascular disease (CVD) is one of the leading
causes of morbidity and mortality in industrialized coun-
tries, despite the advances observed in clinical outcomes
[1, 2]. Preventing and managing CVD in these patients
is a priority objective of healthcare systems [2, 3]. The
importance of prevention is therefore unquestionable,
and must be applied at different levels: a) in the general
population, by promoting healthy lifestyle habits, and b)
individually, for individuals with moderate/high risk of
CVD or established CVD, and reducing high cardiovas-
cular risk factors such as hypertension and dyslipidemia
[3–5]. Dyslipidemias are a set of asymptomatic diseases
caused by abnormal blood lipoprotein concentrations,
and are one of the major risk factors for cardiovascular
diseases in adults [5]. Drug therapy forms one of the
bases of treatment; lipid-lowering agents in general, and
statins in particular (simvastatin, atorvastatin, etc.), are
drugs that reduce cholesterol synthesis in the liver by a
mechanism of competitive inhibition with HMG-CoA
reductase [6]. In spite of evidence supporting the efficacy
of statins in the prevention of major cardiovascular
events, lack of treatment adherence continues to be a
considerable problem [7]. Several studies have shown
that lack of adherence to statin treatment remains above
50% [6–8]. Thus, long-term therapeutic non-compliance
is one of the major problems in daily practice, as it re-
sults in lower clinical effectiveness, lack of achievement
of treatment goals and a possible increase in the use of
healthcare resources [9]. Some factors associated with
lack of adherence to statin treatment have been identi-
fied, such as: their use in primary prevention, low eco-
nomic income, young age, poly-medication, absence of
symptoms, psychological comorbidities, adverse reac-
tions and/or unhealthy lifestyle habits [9, 10].
At present, both brand-name and generic presentations
are available for statin therapy of high blood cholesterol
levels. Generics are drugs that are bioequivalent to the ori-
ginal brand name and have the same levels of efficacy,
safety and quality [11]. Factors that may influence their
use in routine medical practice include physician aware-
ness and local or national healthcare intervention strat-
egies with respect to generic drugs [12]. It should be
noted that current policies in Spain regarding the price
restriction of brand-name versus generic drugs no longer
constitute such a solid argument as to demand their use
at the same price (reference prices require price equality
that can be financed by the Spanish National Health Sys-
tem –NHS-) [13].Discrepancies are seen between argu-
ments in favor of and against prescribing generic drugs
[14, 15]. The disadvantage of a generic drug is the confu-
sion it may cause for patients regarding its commercial
name (active substance) and its presentation or form
(bio-appearance), especially in older people [14, 16, 17].
This potential confusion may lead to medication errors,
which could in turn lead to treatment non-adherence,
cause a possible decrease in clinical effectiveness, trigger
the onset of adverse effects and generate a potential in-
crease in associated healthcare costs [18–20]. The change
in pill appearance (physical characteristics of shape, color,
size and packaging that identify medicines) which occurs
when generic drugs are supplied by different brands over
time might result in higher levels of treatment discontinu-
ation or mean that patients are less likely to adhere to
treatment [19]. Therefore, administration of a generic
drug could be considered a factor to be taken into ac-
count, particularly in some countries, like Spain, where
generic substitution is allowed and their governments en-
courage doctors to prescribe them. Pharmacists can make
a substitution between generics, choosing one from those
available in the national reference pricing system, unless
the doctor and/or the patient prefer another product [19].
Treatment persistence constitutes a key factor in disease
progression and risk of complications [20]. Confirming
this hypothesis (link between treatment persistence vs.
clinical and economic consequences) with the same active
substance would render the conclusions more robust.
While there are other data sources, including claims da-
tabases, patient registries, internet-based consumer re-
search and prescription-based data collection, this article
focuses on the evidence with respect to behaviors in Spain.
This allows for an established method of researching
current treatment practices across a wide range of disease
areas using robust, real-world data that accurately reflect
current symptom prevalence and severity as well as asso-
ciated treatment practices for a number of common
chronic disease areas. This article provides real-world evi-
dence on treatment persistence and medication possession
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as well as clinical (patients reaching goals and incidence of
a cardiovascular event) and economic consequences of
generic versus brand-name drugs used in routine clinical
practice to treat high blood cholesterol levels with statins.
Methods
Design
In order to provide real-world evidence of treatment
persistence and economic and patient outcomes of gen-
eric versus brand-name statin drugs routinely used to
treat high cholesterol levels in Spain, we hypothesized
that using generics would be associated with lower per-
sistence and a lower medication possession ratio (worse
drug adherence) than their counterpart brand-name sta-
tins. This could be due to the impact of different
bio-appearances of generics among them and versus
brand-name statins. To answer such hypotheses, this
paper reported the findings of a secondary investiga-
tional analysis conducted by ClinicResearch that was
submitted and approved by the Institutional Research
Board of the Universitat Internacional de Catalunya in
Barcelona and the Spanish Agency of Medicines. This
research used existing anonymized electronic medical
records (EMRs) linked to the patient database of the
RedISS Foundation (http://rediss.es/). The RedISS Foun-
dation is a research network whose primary goals are to
carry out research on the services provided by healthcare
management organizations in Spain. RedISS is a longitu-
dinal, anonymized database of EMRs kept by primary
healthcare physicians across Spain. The patient data in-
cluded in the database are stripped of identifying details
as specified in Spanish Law 15/1999, of 13 December, on
Personal Data Protection. For the findings presented
here, primary healthcare centers in two regions (Catalo-
nia and Asturias) provided patient data in the form of
clinical records for over 343,182 actively registered indi-
viduals. These two regions were selected because of the
availability of data to cover the longitudinal period of
the research. The data are representative of the Spanish
population. The data available include information on
demographics, medical history (including diagnoses and
health contacts), results of clinical research, drug pre-
scriptions and days of sick leave. Diagnostic data are re-
corded using the International Classification of Primary
Care version 2 (ICPC-2) and/or the International Statis-
tical Classification of Diseases and Related Health Prob-
lems (Ninth Revision) codes [21].
Patient and public involvement
Patients or the public were not involved directly in this
work, but EMRs were abstracted from the database to
carry out the analysis. Records with a diagnosis of hyper-
cholesterolemia were identified in the database based on
patients’ medical and treatment history. Patients first
prescribed atorvastatin or simvastatin (brand-name or
generic) between July 1, 2010, and June 30, 2012, were
eligible to enroll. The inclusion criteria were as follows:
male or female, 18 years of age or older, having been en-
tered in the database 12 or more months before first be-
ing prescribed atorvastatin or simvastatin, having been
enrolled in the long-term prescription follow-up pro-
gram at each healthcare center, having received ≥2 pre-
scriptions for generic or brand-name statins and having
been diagnosed with hypercholesterolemia before the
date of enrollment, with at least 2 follow-up contacts in
the database. Patients first prescribed atorvastatin or
simvastatin after June 30, 2012, and patients who might
have been exposed to these statins within 12months of
the index date, were excluded. Patients who received
combination therapy with concomitant or sequential
generic or brand-name statins were considered ineligible
for the analysis, as were those receiving a statin different
from the two evaluated here. The EMRs of patients
whose healthcare was transferred out to other regions or
healthcare centers during the follow-up period were also
excluded. From these data, four subgroups of thera-
peutic regimens were identified according to the Ana-
tomical Therapeutic Chemical (ATC) classification
system [22]: brand-name atorvastatin, generic atorva-
statin, brand-name simvastatin and generic simvastatin
(ATC, atorvastatin: C10AA05; simvastatin: C10AA01).
The index date was defined as the date on which a pa-
tient was first prescribed either a brand-name or generic
statin. Patients were followed up until the earliest date
among the following options: the index date plus 60
months; the completion of recorded data; the last pre-
scription for the regimen of interest plus 30 days; or the
date of regimen change. The recorded data completion
date was defined as the earliest date from among the fol-
lowing: the last date on which data was collected for the
practice, the incidence of a cardiovascular event or the
date of all-cause mortality. The initial analysis plan in-
cluded obtaining all available records that met all the
screening criteria in the enrollment period (from the
index date). Therefore, no initial predetermination of the
minimum sample size was performed. EMRs fulfilling
inclusion and exclusion criteria as mentioned above
were abstracted in one shot and transferred to a data-
base in Microsoft Access software, then, transferred to a
statistical package (IBMSPSS v20) for analysis. The ab-
straction was performed by means of an algorithm
which included all variables described in the following
sections of methods.
Diagnosis and demographics
The records of patients with hypercholesterolemia were ob-
tained from the International Classification of Primary Care
(ICPC-2; T93) [21] and/or the International Classification
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of Diseases (Ninth Revision), Clinical Modification (ICD-
9-CM; 272.0). The diagnosis of hypercholesterolemia was
always at the physician’s discretion, following scientific soci-
ety recommendations (2016 European Society of Cardi-
ology/European Atherosclerosis Society Guidelines for the
Management of Dyslipidaemias) [3]. The sociodemographic
and comorbidity variables were as follows: age (continuous
and by range) and sex, as well as personal history based on
the ICPC-2 of hypertension (K86, K87), diabetes mellitus
(T89, T90), obesity (T82), active smoking (P17), alcohol
abuse (P15, P16), all types of organ failure (heart, liver and
kidney), ischemic heart disease (codes: K74, K76, K75),
cerebrovascular accident (K90, K91, K93), depressive
syndrome (P76) and malignant neoplasms (all types:
A79, B72–75, D74–78, F75, H75, K72, L71, L97, N74–76,
T71–73, U75–79, W72–73, X75–81, Y77–79). As a sum-
mary variable of the general comorbidity, for each patient
treated, the following were used: a) the Charlson comor-
bidity index [23], as an approximation to the severity of
the patient, b) the number of chronic comorbidities and c)
the case-mix index, based on adjusted clinical groups, a
system for classifying patients according to similar re-
source consumption [24].
Treatments
Two groups were distinguished based on the initial treat-
ment: a) brand-name statins, and b) generic statins, with
no combinations. The follow-up period was 5 years, start-
ing from the date of patient inclusion. The index date was
the treatment (atorvastatin or simvastatin) start date,
while the end date was whichever of the following oc-
curred first: a) end of follow up date (5 years follow-up), b)
occurrence of a cardiovascular event/death, c) switch to
another lipid-lowering treatment other than the one that
led to the patient’s inclusion, and d) cessation/abandon-
ment of the medication. The information was obtained
from the drug supply records for drugs. The choice of
brand-name or generic drug for a specific patient was at
the physician’s discretion (routine clinical practice). To
fulfill the initial analysis plan according to the objective of
this research, records of simvastatin and atorvastatin were
separated into two groups depending on whether they
included a brand-name or a generic statin (see
Additional file 1: Tables S1 and S2 and Table 2). Patients
first prescribed atorvastatin or simvastatin (brand-name
or generic) between July 1, 2010, and June 30, 2012, were
eligible to enroll. Only atorvastatin and simvastatin were
selected, for several reasons: a) they are the most widely
used lipid-lowering drugs in Spain (between 91 and 94%
of the market share among statins with generic presenta-
tions available in the years of abstraction) [25], b) they are
available in brand-name and generic presentations over a
long period of time, which makes them suitable for pro-
longed follow-up, c) both statins are indicated to lower
high blood cholesterol levels [6], d) the variability in out-
comes is reduced considerably on analyzing only two sta-
tins, and e) there is little evidence regarding the
relationship between these variables in real life, in either
the international literature or in our healthcare setting, so
this research may be of interest.
Outcomes
Adherence
The adherence rate was defined according to the criteria
of the International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) and calculated based on
use/medication possession ratio (MPR) and treatment
persistence [26]. MPR was assessed from the first to the
last prescription and represents the number of days of
medication supplied divided by the number of treatment
days (from the index date). Persistence was defined as
the time, measured in days, without stopping the initial
treatment or switching to another medication at least
30 days after the initial prescription. It is expressed as
the difference between the date of first supply (enroll-
ment) and the date of last supply, plus the number of
days that would be covered by the last supply (30 days).
Resource utilization and cost analysis
The societal and the Spanish NHS perspectives were
taken into account to calculate healthcare and indirect
costs. Healthcare costs (direct costs) were considered to
be those relating to healthcare activity (medical visits,
days of hospitalization, emergency visits, diagnostic and
therapeutic requests, etc.) performed by healthcare pro-
fessionals. Non-healthcare costs (indirect costs) were
considered to be those relating to work productivity loss
(days of sick leave due to temporary disability). Cost was
expressed as mean cost per patient (average per unit)
throughout the analysis period. Table 1 shows unitary
costs of healthcare resources and days of sick leave ap-
plied in the economic valuations (in € for year 2016).
Prices were based on the sites’ analytical accounting, ex-
cept medication and days of sick leave. Medications were
quantified by retail price per pack at the time of dispens-
ing from the Community Pharmacy (according to the
Drug Catalogue of the General Council of Associations
of Official Pharmacists of Spain. Available from: https://
botplusweb.portalfarma.com/). For this research, beside
statins which both brand-name and generic have the
same reference price to be funded by the NHS, the cost
of medication included all drugs related with treatment
of any possible cardiovascular risk factor and were quan-
tified at their recommended retail price as this is the
price funded by the NHS normally.
Days of occupational disability and productivity losses
were quantified according to the average inter-professional
wage (source: Spanish Statistical Office [Instituto Nacional
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de Estadística, INE]) [27]. The analysis did not take into
account non-healthcare direct costs, i.e., “out-of-pocket”
costs or costs paid by the patient/family, as these are not
recorded in the database and patients themselves could
not be accessed through the retrospective collection of
existing records.
Clinical effectiveness
The following clinical chemistry parameters obtained at
the start and end of the follow-up were considered: total
cholesterol, serum triglycerides, high-density lipoprotein
cholesterol (HDL-c) and low-density lipoprotein choles-
terol (LDL-c) in mg/dL. As an approximation to the clin-
ical effectiveness, the following were considered: 1) The
achievement of therapeutic goals, which was evaluated
based on the patient’s LDL-c value (reduction in mean
and percentage). The therapeutic goal was considered to
be achieved for LDL-c levels ≤2.59mmol/L (100mg/dL)
or 1.81mmol/L (70mg/dL), depending on whether a car-
diovascular event would already have occurred or not, re-
spectively [3]. The measurement was taken at the start
(index date) and end of the follow-up period (value closest
to the date), 2) Incidence of a cardiovascular event during
the 5-year follow-up, differentiating: a) ischemic heart dis-
ease (angina, acute myocardial infarction), and b) cerebro-
vascular accident (transient ischemic attack, stroke); and
3) death of the patient (all-cause mortality). Both the inci-
dence of a cardiovascular event and all-cause mortality
were expressed in the form of incidence (density) rate,
and calculated as the ratio between the number of new
cases that occurred during the follow-up period and the
sum of the risk periods of each of the individual patients
throughout the period specified. This rate was measured
in observed cases per 1000 person-years.
Statistical analysis
Basic descriptive statistics, such as means and proportions
not requiring statistical comparisons, are presented in ta-
bles by group of interest in the analysis. Analyses requiring
statistical comparisons were performed using SPSS Ver-
sion 17 (SPSS Inc., Chicago, USA). The normality of the
distribution was verified using the Kolmogorov–Smirnov
test. Standard parametric and non-parametric univariate
statistical tests suitable for both the data type and the
comparison group were performed. In making compari-
sons across patient subgroups within the RedISS sample,
maximum likelihood/regression models were applied to
isolate the influence of each possible explanatory variable
on the outcome parameter of interest. These included
generalized linear models [28, 29]. To fulfill the initial ana-
lysis plan according to the objective, records from simva-
statin and atorvastatin were separated into two groups
depending on whether they included a brand-name or a
generic statin. Before this, homogeneity of records for
each statin, comparing brand-name versus generic was
carried out to identify possible sources of heterogeneity
within the same drug. Standard univariate analysis was
carried out (see Additional file 1: Tables S1 and S2).
The Mantel-Haenszel Chi-square test was applied to
calculate p values in comparisons of unadjusted incidence
rates for cardiovascular events and all-cause mortality be-
tween generic and brand-name statins. Multivariate ana-
lyses adjusted for covariates were applied to compare
primary endpoints between brand-name and generic sta-
tins. Binary multivariate logistic regression was used to
calculate the odds ratio (OR) adjusted by age, sex, number
of comorbidities, Charlson index, resource utilization
band (RUB), proportion of subjects reaching their LDL-c
goal at the start of therapy and statin type of the difference
in the percentage of patients reaching their LDL-c goals at
discontinuation. A multivariate Cox proportional regres-
sion model was applied to calculate cumulative probability
of persistence with initial statin therapy during the 5-year
follow-up period in the whole sample, in patients without
previous cardiovascular events, as well as with a previous
cardiovascular event. The hazard ratios (HRs) were ad-
justed by age, sex, number of comorbidities, Charlson
index, RUB, proportion of subjects reaching their LDL-c
goal at the start of therapy and statin type. Adjusted HR
relative to brand-name statin of the incidence of both car-
diovascular events or all-cause mortality were also fitted
using a Cox proportional risk model with covariates (age,
sex, number of comorbidities, Charlson index, RUB, pro-
portion of subjects reaching their LDL-c goal at the start
of therapy, statin type and prior cardiovascular event. Dif-
ferences in costs between brand-name and generic statins
Table 1 Breakdown of costs per unit and work productivity
losses (2016)
Healthcare and non-healthcare resources Unit costs (€)
Medical visits
Primary care medical visit 23.19
Emergency medical visit 117.53
Hospitalization (one day) 320.90






Work productivity — Indirect costs
Cost per day not worked 101.21
Source of healthcare resources: analytical accounting done by the authors and
the INE. RRP: recommended retail price. Values are expressed in euros
aOnly in respiratory medicine, cardiology, endocrinology and internal
medicine departments
bRelated to plasma lipid assessment
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were compared using analysis of variance (ANOVA) for
unadjusted costs and general linear models adjusted for
age, sex, number of comorbidities, Charlson index, RUB,
proportion of subjects reaching their LDL-c goal at the
start of therapy, statin type, prior cardiovascular event and
treatment duration. A 95% confidence interval (CI) of the
differences was calculated with 1000 non-parametric boot-
strap iterations.
Reporting guidelines
Consolidated Health Economic Evaluation Reporting
Standards (CHEERS) reporting guidelines were used to
write this article [30].
Results
From an initial screening, 343,182 EMRs of subjects 18 or
more years of age were assigned to the sites and 13,244 re-
cords fulfilling enrollment criteria were recruited (Fig. 1).
EMRs of patients receiving brand-name or generic statins
were classified into 4 groups: brand-name atorvastatin
(N = 1313; 20.9%), generic atorvastatin (N = 4957;
79.1%), brand-name simvastatin (N = 1694; 24.3%) and
generic simvastatin (N = 5280; 75.7%), to test the
homogeneity of brand-name versus generic within the
same statin. Additional file 1: Tables S1 and S2 shows
the baseline characteristics of patients analyzed ac-
cording to the type of statin received before separat-
ing records into two groups: brand-name and generic
statin, and the dosages used. Table 2 shows the demo-
graphic characteristics and comorbidities from the EMRs
according to the use of generic or brand-name statins. Just
over three-quarters of records (77.3%) corresponded to
generic statins, with 52.7% corresponding to simvastatin.
Mean age was 61.3 (standard deviation [SD]: 11.4) years
and 52.6% were women. Significant differences at p < 0.05
level were not observed in the main characteristics ac-
cording to type of statin, although presence of alcoholism,
ischemic heart disease and cerebrovascular accident were
at p < 0.1 level.
Treatment persistence, MPR and doses administered
are detailed in Table 3. Mean duration (SD) of generic
statin treatment was significantly shorter than with
brand-name statins: 32.0 (20.2) vs. 34.2 (20.5), p < 0.001),
and the MPR was also significantly lower: 61.5% vs.
65.1%; p < 0.001. A significantly lower percentage of
patients continued taking generic statins compared to
brand-name statins at 60 months of follow-up (persist-
ence): 20.7% vs. 25.9% with a hazard ratio (HR) 14%
lower on average relative to the brand-name statin:
0.86 (95% CI: 0.82–0.91, p < 0.001). Treatment persist-
ence was significantly lower from 12 months after the
start of therapy: 77.7% vs. 80.3%, HR: 0.81 (0.74–0.89),
p < 0.001 (Table 3, Fig. 2).
The distribution of the different clinical chemistry pa-
rameters, therapeutic goals, incidence of cardiovascular
events and all-cause mortality according to group analyzed
Fig. 1 Flow diagram showing the selection procedure of patient electronic medical records for the investigational analysis. EMR = Electronic
Medical Records. Population of reference and eligibility criteria are included in the text
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are detailed in Table 4. While no significant differences
were observed in the lipid parameters or in the percentage
of patients who met their therapeutic goals at the start of
the statin treatments, the probability of reaching their
therapeutic goals during the 60-month follow-up period
was on average 13% lower with the generic compared
to with the brand-name statins; OR: 0.87 (0.80–0.95),
p = 0.003; as a result, 39.2% of patients met their
therapeutic goals with generic vs. 42.0% with brand-name
statins. These findings were due to the significantly lower
reduction in LDL-c levels with generic compared to
brand-name statins: − 13.6mg/dL vs. -17.0 mg/dL, re-
spectively; p < 0.001 (Table 4). The crude incidence rate of
cardiovascular events in number of cases per 1000 per-
son-years was significantly higher in those who re-
ceived therapy with generics compared to those with
brand-name statins: 39.56 (37.24–41.99) vs. 31.48
(27.85–35.46), p < 0.001, with a 31% higher adjusted haz-
ard ratio for having an event, HR: 1.31 (1.15–1.50),
p < 0.001 (Fig. 3). These results were observed for
both stroke and coronary events (Table 4). Likewise,
the crude rate of all-cause mortality was significantly
higher in those who received generic statins: 25.09
(23.25–27.04) vs. 18.82 (16.03–21.95). p < 0.001, with a
36% higher adjusted hazard ratio for death, HR: 1.36
(1.15–1.62), p < 0.001 (Fig. 4).
Table 2 Characteristics (demographics and comorbidity) at the start of therapy with generic or brand-name statin
Group Brand-name Generic Total p
Number of patients (%) 3007 (22.7%) 10,237 (77.3%) 13,244 (100%)
Sociodemographic characteristics
Average age (years) 61.4 (11.7) 61.2 (11.3) 61.3 (11.4) 0.501
Ranges:
18–44 years 7.2% 7.7% 7.6%
45–64 years 52.9% 51.9% 52.1%
65–74 years 23.0% 25.9% 25.2%
≥ 75 years 16.8% 14.6% 15.1% 0.234
Sex (female) 52.7% 52.5% 52.6% 0.827
Pensioners 50.2% 51.6% 50.5% 0.191
General comorbidity
Average diagnoses 6.6 (3.6) 6.5 (3.3) 6.5 (3.3) 0.502
Charlson index 0.7 (1.0) 0.7 (1.0) 0.7 (1.0) 0.855
Average RUB 2.9 (0.7) 3.0 (0.7) 3.0 (0.7) 0.527
1 (very low comorbidity) 3.9% 3.4% 3.5%
2 (low comorbidity) 15.4% 14.8% 14.9%
3 (moderate comorbidity) 65.5% 66.7% 66.4%
4 (high comorbidity) 13.2% 13.2% 13.2%
5 (very high comorbidity) 2.1% 1.9% 1.9%
Associated comorbidities
Hypertension 50.2% 51.6% 50.5% 0.191
Diabetes mellitus 22.8% 23.0% 22.9% 0.786
Obesity 19.4% 19.8% 19.5% 0.658
Active smokers 24.0% 22.9% 23.7% 0.224
Alcoholism 3.5% 4.2% 3.7% 0.064
Ischemic heart disease 8.3% 9.4% 8.5% 0.057
Cerebrovascular accident 11.0% 9.9% 10.8% 0.091
Previous cardiovascular event 19.0% 18.3% 18.8% 0.382
Organ failure 17.3% 17.7% 17.4% 0.675
Dementia 2.4% 2.5% 2.5% 0.792
Depressive syndrome 21.5% 21.4% 21.5% 0.182
Malignant neoplasms 9.4% 9.0% 9.3% 0.537
Values expressed as percentage or mean (standard deviation), p statistical significance between brand-name vs. generic, RUB resource utilization band
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Table 3 Treatment persistence and medication possession ratio administered by group
Group Brand-name Generic Total p
Number of patients (%) 3007 (22.7%) 10, 237 (77.3%) 13,244 (100%)
Time since diagnosis (months) 2.2 (2.4) 2.2 (2.3) 2.2 (2.4) 0.892
Median (P25–P75) 2.0 (1.0–3.0) 2.0 (1.0–3.0) 2.0 (1.0–3.0)
Treatment possession (months) 22.3 (20.2) 19.6 (21.7) 20.2 (21.2) < 0.001
Median (P25–P75) 21.0 (12.0–44.0) 19.0 (10.0–38.0) 20.0 (10.0–42.0)
Treatment duration (months) 34.2 (20.5) 32.0 (20.2) 32.5 (20.3) < 0.001
Median (P25–P75) 31.0 (15.0–60.0) 29.0 (14.0–55.0) 29.0 (14.0–56.0)
Medication Possession Ratio
Average 65.1% 61.5% 62.3% < 0.001
95% CI 63.8–66.2% 60.1–62.2% 61.8–62.9%
Percentage of patients on treatment at different cut-off point Treatment persistence (HR [95% CI])a
12 months 80.3% 77.7% 78.3% 0.81 [0.74–0.89], p < 0.001
24months 60.9% 56.9% 57.8% 0.93 [0.87–0.99], p = 0.021
60months 25.9% 20.7% 21.9% 0.86 [0.82–0.91], p < 0.001
Values expressed as percentage or mean (SD standard deviation), p brand-name vs. generic, CI confidence interval, P25 25th percentile, P75 75th percentile
aHR adjusted hazard ratio relative to brand-name statin (adjusted using a Cox proportional risk model with covariates (age, sex, number of comorbidities, Charlson
index, resource utilization band, proportion of subjects reaching their LDL-cholesterol goal at the start of therapy, statin type and prior cardiovascular event); P percentile













A B C 
HR: 0.86 [0.82-0.91], p<0.001 HR: 0.86 [0.82-0.91], p<0.001 HR: 0.88 [0.78-0.99], p=0.034 
Brand-name statins 
Generic statins 
Fig. 2 Cumulative probability of persistence with initial statin therapy during the 5-year follow-up period. Probability in the whole sample (graph a),
patients without previous cardiovascular events (graph b) or with previous cardiovascular events (graph c). HR: Hazard Ratio with 95% confidence
interval adjusted by age, sex, number of comorbidities, Charlson index, resource utilization band (RUB), proportion of subjects reaching
their LDL-cholesterol goal at the start of therapy and statin type
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Table 5 shows the comparison of brand-name vs. gen-
eric statins in resource use and costs. Of the total costs,
70.4% corresponded to healthcare costs (direct) and 29.6%
to non-healthcare costs (productivity losses due to sick
leave). Subjects undergoing treatment with brand-name
statins used fewer healthcare resources, specifically in
primary care visits (48.1 vs. 56.4; p < 0.001), specialized
care visits (8.3 vs. 10.0; p < 0.001) and hospital emergen-
cies (7.0 vs. 8.3; p < 0.001). The average per unit of the
annual total cost (95% CI) of subjects undergoing treat-
ment with brand-name vs. generic statins corrected for
covariates was lower: €11,574 (11,103-12,045) vs.
€12,978 (12,762-13,194), p = 0.001; difference: -€1404
(885–1922) in 60 months of follow-up. These differ-
ences were mainly due to lower healthcare costs: €7980
(7853-8808) vs. €9118, (9059-9176), p < 0.001; the work
productivity losses, while lower, did not reach statistical
significance.
Analysis according to previous occurrence of a
cardiovascular event
The lower probability of persistence at 60 months with
generic statins was observed both in the overall sample
and when this was divided into two subgroups according
to previous occurrence of a cardiovascular event (Fig. 2);
the likelihood of continuing to receive a statin was, re-
spectively, 14% or 12% lower on average for the generic
statin in patients without and with a previous cardiovascu-
lar event (p < 0.05 in both cases). Table 6 shows the main
variables according to the absence/presence of previous
cardiovascular events. In the absence of previous CVD,
patients using generic vs. brand-name statins showed
lower achievement of the therapeutic goals: 37.2% vs.
39.46%, OR: 0.89 (0.80–0.99), p = 0.025. Similar results
were observed in patients with a previous cardiovascular
event: 48.0% vs. 53.56%, OR: 0.78 (0.64–0.95), p = 0.015.
The crude incidence rate of cardiovascular events in
Table 4 Patient Outcomes: lipid panel variations, patients who have reached their lipid goals and incidence rate of cardiovascular
events and all-cause mortality
Group Brand-name Generic Total p
Number of patients (%) 3007 (22.7%) 10,237 (77.3%) 13,244 (100%)
Clinical chemistry parameters
Total cholesterol, mg/dL; initial 223.9 [222.7–225.1] 223.2 [222.4–224.0] 223.3 [222.8–223.8] 0.489
Total cholesterol, mg/dL; final 189.4 [188.1–190.7] 192.8 [191.9–193.7] 192.0 [191.4–192.6] < 0.001
Difference (initial – final) −34.5 −30.4 −31.3 < 0.001
Triglycerides, mg/dL; initial 141.7 [140.2–143.2] 142.5 [141.6–143.4] 142.3 [141.7–142.9] 0.619
Triglycerides, mg/dL: final 129.8 [128.5–131.1] 133.8 [133.1–134.5] 132.9 [132.4–133.4] 0.014
Difference (initial – final) −11.9 −8.7 −9.4 < 0.001
High-density lipoprotein cholesterol, mg/dL; initial 50.1 [48.3–51.9] 50.2 [49.0–51.4] 50.2 [49.3–51.1] 0.993
High-density lipoprotein cholesterol, mg/dL; final 55.7 [53.8–57.6] 54.3 [53.0–55.6] 54.5 [53.6–55.4] < 0.001
Difference (initial – final) 5.6 4.1 4.3 0.035
Low-density lipoprotein cholesterol, mg/dL; initial 135.6 [133.7–137.5] 135.1 [133.6–136.6] 135.2 [134.3–136.1] 0.485
Low-density lipoprotein cholesterol, mg/dL; final 118.6 [116.8–120.4] 121.5 [120.1–123.0] 120.8 [120.2–121.4] < 0.001
Difference (initial – final) −17.0 −13.6 −14.4 < 0.001
Patients who have reached LDL-c goal (%)*
At the start of statin therapy 17.9 [16.5–19.3] 17.7 [16.9–18.4] 17.7 [17.1–18.4] 0.811
At discontinuation 42.0 [40.2–43.7] 39.2 [38.3–40.2] 39.9 [39.0–40.7] OR; 0.87 [0.80–0.95],
p = 0.003
Absolute variation 24.1 21.5 22.2 < 0.001
Patient Outcomes (IR)**
- Any cardiovascular event 31.48 [27.85–35.46] 39.56 [37.24–41.99] 37.63 [35.65–39.69] < 0.001
CHD event 14.41 [11.98–17.18] 18.76 [17.17–20.45] 17.71 [16.36–19.14] 0.008
Stroke 17.08 [14.43–20.07] 20.81 [19.13–22.59] 19.91 [18.48–21.43] 0.033
- All-cause mortality 18.82 [16.03–21.95] 25.09 [23.25–27.04] 23.59 [22.03–25.23] < 0.001
Values expressed as mean with standard deviation or 95% confidence interval in brackets, CHD: Coronary Heart Disease; IR: unadjusted cumulative incidence rate
in number of cases per 1000 person-years, *OR: Odds ratio, adjusted by age, sex, number of comorbidities, Charlson index, resource utilization band (RUB),
proportion of subjects reaching their LDL-cholesterol (LDL-c) goal at the start of therapy, statin type and prior cardiovascular event; **p values using the Mantel-
Haenszel Chi-square test
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number of cases per 1000 person-years was higher in
those who received therapy with generics than with
brand-name statins (Table 6), particularly in subjects with
a previous history of a cardiovascular event, with an ad-
justed hazard ratio for having an event between 22
and 44% higher according to whether they had or did
not have a previous event, respectively, HR: 1.22
(1.02–1.44)], p = 0.027 and HR: 1.44 (1.16–1.77), p =
0.001 (Fig. 3). Similarly, the crude rate of all-cause mortal-
ity was higher in those who received generic statins, espe-
cially in patients with previous CVD, with an adjusted
hazard ratio for death between 26 and 62% higher in
patients receiving generic statins: HR: 1.26 (1.02–1.55),
p = 0.031 and HR: 1.62 [1.20–2.19], p = 0.002, respect-
ively (Fig. 4).
Table 6 also shows the comparison of brand-name vs.
generic statins in resource use and costs. The average per
unit of the annual total cost (95% CI) of subjects undergo-
ing treatment with brand-name vs. generic statins cor-
rected for covariates was significantly lower, both in the
absence and presence of previous CVD; adjusted differ-
ences of 734 [516–952], p = 0.001 and 2107 [1805-2409];
p < 0.001, respectively, at 60months of follow-up. These
differences were also due to lower healthcare costs.
Discussion
A generic drug is known to have the same qualitative and
quantitative composition in terms of active substance and
pharmaceutical form as the reference (brand-name) medi-
cinal product, with proven bioequivalence (bioavailability)
[13]. Nevertheless, generic versus brand-name drugs may
differ in terms of excipient composition and outer appear-
ance, which may result in problems of bio-appearance
(type of packaging, tablet form, etc.), particularly for aging
patients who are taken several medicines concomitantly
[19, 24]. In Spain, the entry into the market of these drugs
has helped to reduce pharmaceutical expenditure for the
Spanish NHS, although, at present, both generic and
brand-name drugs have the same acquisition cost as there
is a reference price system for funded medicines [13]. In
view of this, there should be no pharmacological argu-
ments that indiscriminately prevent the prescription of
















HR: 1.31 [1.15-1.50], p<0.001 HR: 1.44 [1.16-1.77], p=0.001HR: 1.22 [1.02-1.44], p=0.027
Fig. 3 Cumulative probability of cardiovascular event with initial statin therapy during the 5-year follow-up period. Probability in the whole
sample (graph a), patients without previous cardiovascular events (graph b) or with previous cardiovascular events (graph c). HR: Hazard Ratio
with 95% confidence interval adjusted by age, sex, number of comorbidities, Charlson index, resource utilization band (RUB), proportion of
subjects reaching their LDL-cholesterol goal at the start of therapy and statin type
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The findings observed in this retrospective investiga-
tional research reveal that patients who started treat-
ment with a generic statin compared to the brand-name
drug were associated with lower treatment adherence, in
terms of both percentage of days with medication pos-
session (MPR ratio) and also days of persistence, which
translated into poorer clinical outcomes (reduction in
LDL-c levels, incidence of CVE), resulting in higher use
of resources and sizeable healthcare costs for the Span-
ish NHS. The large sample size obtained, a long 5-year
follow-up period, and consistency of outcomes with the
two molecules studied should be considered strength of
the investigation. It should be noted that there are few
observational studies in real-world conditions in the lit-
erature consulted which, while it makes it difficult to
compare results, highlights the fact that this investiga-
tion is unique. Thus, these findings might be considered
of clinical and economic relevance. Persistence and ad-
herence over time during the 5-year follow-up period
were poor both for generics and for brand-name as well,
although significantly worst for generic drugs. In this re-
spect, abundant evidence shows that between 25 and
50% of patients fail to comply with treatment in the first
2 years of therapy [6–8]. Our figures are similar to or
perhaps slightly higher than those reported (though still
low). There might be several explanations for this: a) our
method of measuring persistence, b) the dose indicated
by the physician when initiating the treatment, c) ours is
a more recent study, d) these are patients who require
care (regularly attend check-ups), and/or e) they are subject
to specific follow-up nursing care. Nonetheless, our results
are consistent with other published findings [9, 10, 26]. In
this respect, as well as known reasons for non-adherence,
which may be intentional (sociodemographic factors, side
effects, lack of understanding of treatment or health status,
etc.) or unintentional (failure to remember how to take the
medication correctly, etc.), the results of the investiga-
tion show that administration of a generic drug could
be considered an additional factor to be taken into ac-
count [17, 19, 26, 31]. The appearance of the medicinal
product (not measured in the investigation) might in-
fluence our results and affect the poorer adherence
seen with generic drugs here. These factors include a
different appearance (in terms of color and shape), a
Survival time (months)















Fig. 4 Cumulative probability of all-cause mortality with initial statin therapy during the 5-year follow-up period. Probability in the whole sample
(graph a), patients without previous cardiovascular events (graph b) or with previous cardiovascular events (graph c). HR: Hazard Ratio with 95%
confidence interval adjusted by age, sex, number of comorbidities, Charlson index, resource utilization band (RUB), proportion of subjects reaching
their LDL-cholesterol goal at the start of therapy and statin type
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lack of certain presentations (delayed release or delayed
absorption), variability in terms of excipients, a copay-
ment effect or even a nocebo effect [31, 32].
The use of resources and costs were lower in patients
treated with brand-name vs. generic drugs. The temporal
relationship between lack of adherence and worst persist-
ence, lower clinical effectiveness and greater use of health-
care resources is beyond doubt, and is consistent with the
literature consulted [31–35]. Our research found such
poorer persistence for the generic statin; approximately the
probability of keeping taken the original therapy was a 14%
lower with generics than with brand names, and this was
regardless of the occurrence of a previous CVE [32, 33, 36].
Moreover, patients undergoing treatment with generic sta-
tins showed lower reduction in their therapeutic goals than
those receiving a brand-name statin (approximately 13%
chance). As a consequence, and after adjusting for con-
founding covariates, it should be noted that with generics
the probability of suffering a CVE was higher on an average
31% during the 5-year follow-up (22 to 44% depending of
previous occurrence of a CVE). Also, the adjusted probabil-
ity of all-cause death was significantly higher with generics
(on an average 36%), and this was irrespective of previous
occurrence of a CVE; 26% in subjects with no previous
Table 5 Resource utilization and associated costs (€) by group
Group Brand-name Generic Total P
Number of patients (%) 3007 (22.7%) 10,237 (77.3%) 13,244 (100%)
Resource utilization
Medical visits (primary care) 48.1 (27.0) 56.4 (26.4) 54.5 (26.8) < 0.001
Laboratory tests 14.3 (9.7) 17.1 (10.3) 16.4 (10.2 < 0.001
Conventional radiology 8.0 (7.6) 10.7 (7.7) 10.1 (7.7) < 0.001
Complementary tests 11.4 (4.4) 15.2 (4.2) 14.3 (4.5) < 0.001
Days of hospitalization 1.1 (3.8) 1.8 (5.6) 1.6 (5.2) < 0.001
Medical visits (hospital) 8.3 (7.4) 10.0 (7.9) 9.6 (7.8) < 0.001
Emergency room visits (hospital) 7.0 (9.0) 8.3 (9.8) 8.0 (9.7) < 0.001
Days of occupational disability 36.6 (101.1) 37.6 (105.0) 37.4 (104.1) 0.636
Unadjusted costs
Healthcare costs 8246 (3699) 9071 (4093) 8927 (4039) < 0.001
Costs in primary care 6320 (2658) 6605 (2657) 6555 (2659) < 0.001
Medical visits 1105 (630) 1307 (613) 1272 (620) < 0.001
Laboratory tests 315 (213) 380 (229) 369 (228) < 0.001
Conventional radiology 149 (142) 199 (142) 190 (143) < 0.001
Complementary tests 438 (169) 578 (158) 553 (169) < 0.001
Drugsa 4314 (2377) 4141 (2359) 4171 (2363) 0.002
Costs in specialized care 1927 (2136) 2466 (2640) 2372 (2567) < 0.001
Days of hospitalization 332 (1180) 568 (1783) 527 (1696) < 0.001
Medical visits 763 (691) 923 (725) 895 (721) < 0.001
Emergency room visits 832 (1098) 976 (1148) 951 (1141) < 0.001
Non-healthcare costs (productivity loss) 3562 (10076) 3806 (10631) 3764 (10536) 0.327
Total costs (€) 11,808 (10854) 12,877 (11969) 12,691 (11789) < 0.001
Adjusted costsb(€) Brand-name Generic Difference p
Healthcare costs 7980 (7853–8808) 9118 (9059–9176) 1137 (997–1277) < 0.001
Primary care healthcare costs 6070 (6024–6116) 6653 (6632–6674) 583 (532–633) < 0.001
Medication cost 4110 (4041–4178) 4188 (4156–4219) 78 (11–149) 0.028
Specialized healthcare costs 1910 (1805–2016) 2465 (2417–2514) 555 (439–671) < 0.001
Non-healthcare costs (productivity loss) 3594 (3161–4026) 3860 (3662–4058) 267 (101–843) 0.272
Total costs 11,574 (11103–12,045) 12,978 (12762–13,194) 1404 (885–1922) 0.001
Values expressed as mean (SD standard deviation), p brand-name vs. generic, 95% CI 95% confidence interval in parenthesis
aDrugs include statin costs plus all other possible treatments
bAdjusted by age, sex, number of comorbidities, Charlson index, resource utilization band, proportion of subjects reaching their LDL-cholesterol goal at the start of therapy,
statin type, prior cardiovascular event and treatment duration. 95% confidence intervals of the differences calculated with non-parametric 1000 bootstrap iterations
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CVE and 62% with previous CVE. In this aspect, Tran et al.
[37] reported that the use of generic drugs is associated
with a reduction in therapeutic goals of LDL-c in the treat-
ment of dyslipidemia. Gagne et al. [38], in a prospective
study, however found that patients who started treatment
with brand-name versus generic statins had higher rates of
non-adherence and cardiovascular episodes. While these
data cannot be generalized, in fact Gagne et al. pointed out
that such finding could be due to the ample differential ac-
quisition costs of brand-name statins in comparison with
generic in the US, these differences are consistent with
other published studies [33]. On the other hand, not only
poorer clinical outcomes were showed with generic drugs,
but also it was observed a correlates with higher utilization
of resources (all-type healthcare costs in particular, but not
sick leaves), that was translated into significantly higher
costs for the Spanish NHS; on average €1137 per patient
(€614 in subjects without previous CVE and €1660 in pa-
tients with a previous CVE) in a 5-year follow-up period.
This means and extra cost while the patient is on generic
versus brand-name therapy of about €35.5 per patient per
month in healthcare costs (of which €2.4 are drugs). As re-
sources are limited and there are healthcare budget con-
straints, this sizeable cost should alert both clinicians and
Table 6 Main patient outcomes according to previous major cardiovascular event
Group No previous cardiovascular event Previous cardiovascular event
Generic Brand-name p Generic Brand-name p
Number of patients, % N = 8292 (77.1%) N = 2457 (22.9%) N = 1280 (78.0%) N = 550 (22.0%)
Sociodemographics
Age, mean (SD), years 59.9 (11.3) 60.1 (11.6) 0.427 67.0 (9.6) 67.2 (10.3) 0.640
Sex (female) 54.5% 54.9% 0.681 44.1% 42.9% 0.630
Comorbidity
Number of comorbidities 6.3 (3.2) 6.4 (3.5) 0.198 7.5 (3.4) 7.8 (4) 0.087
Charlson index 0.6 (1.0) 0.6 (0.9) 0.675 1.2 (1.0) 1.3 (1.1) 0.935




59.4% 62.6% p = 0.015 71.0% 76.0% p = 0.002
Treatment persistence
(%, HR)*
17.0% 22.8% 0.86 [0.82–0.91];
p < 0.001
36.1% 42.0% 0.88 [0.78–0.99];
p = 0.034
Patients who have reached LDL-c goal (%)**
At the start of statin
therapy
18.5 [17.7–19.3] 18.8 [17.3–20.3] 0.710 14.1 [12.2–16.0] 13.6 [10.8–16.5] 0.764
At discontinuation 37.2 [36.2–38.2] 39.4 [37.5–41.3] OR; 0.89 [0.80–0.99];
p = 0.025
48.0 [45.2–50.7] 53.5 [49.3–57.6] OR; 0.78 [0.64–0.95];
p = 0.015
Absolute variation 18.7 20.6 0.035 33.8 39.8 0.014
Patient Outcomes (IR)***




0.062 74.42 [67.89–81.42] 55.41 [45.41–66.96] 0.006




0.064 39.71 [34.98–44.91] 26.41 [19.67–34.73] 0.007
Costs (€)**** Generic Brand-name Difference Generic Brand-name Difference




























Values expressed as mean with standard deviation or 95% confidence interval (CI) in brackets; IR: unadjusted cumulative incidence rate in number of cases per
1000 person-years, *HR: adjusted hazard ratio relative to brand-name statin (adjusted using a Cox proportional risk model with covariates (age, sex, number of
comorbidities, Charlson index, resource utilization band [RUB], proportion of subjects reaching their LDL-cholesterol (LDL-c) goal at start of therapy, statin type
and prior cardiovascular event); **OR: Odds ratio, adjusted by age, sex, number of comorbidities, Charlson index, RUB, proportion of subjects reaching their LDL-c
goal at the start of therapy and statin type; ***p values using the Mantel-Haenszel Chi-square test.****Adjusted by age, sex, number of comorbidities, Charlson
index, RUB, proportion of subjects reaching their LDL-c goal at the start of therapy, statin type, prior cardiovascular event and treatment duration. 95% CI
calculated with 1000 non-parametric bootstrap iterations
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health decision makers of the Spanish NHS when facing
hypercholesterolemia, as this condition is highly prevalent
in the community [5].
Arguments in favor of and against generic drugs are
not without controversy as commented above [14, 15].
By way of example, reviews conducted by Kesselheim et
al. [39] and Manzoli et al. [40] defended the similar clin-
ical efficacy between the brand-name and the generic
drug. Mano et al. [41], in a retrospective study, reported
that changing from brand-name (N = 147) to generic
atorvastatin (N = 135) did not affect treatment persist-
ence (85.9% vs. 73.5%) in patients, after 180 days of
treatment. On the basis of 266 patients, Loch et al. [42]
concluded that brand-name vs. generic atorvastatin
achieved similar results (total and LDL cholesterol) in
the clinical management of dyslipidemia, except for
HDL-c levels (better with brand-name atorvastatin).
Nevertheless, to our understanding, the following should
be assessed: whether the sample size obtained was ad-
equate (statistical power), where the balance would be
between statistical significance and clinical relevance/im-
pact, and when meta-analyses are performed based on
these studies. Other authors, in contrast, concluded their
publications with a number of recommendations. Can-
dido et al. [43] suggest that the use of a generic drug
may underestimate the effect of adherence to some me-
dicinal products (single dose, delayed absorption); there-
fore, medicinal products administered to patients with
chronic pain should be personalized to better meet anal-
gesic needs and ensure patient safety. Fraeyman et al.
[44], based on a survey of 1636 patients, recommended
highlighting the name of the active substance on medi-
cation packaging labels to prevent health risks, especially
among older patients. Colombo et al. [31] concluded
that their results were consistent with studies supporting
the possibility that a change in the package appearance
each time a new generic drug prescription is dispensed
may create confusion and reduce patient adherence,
which may in turn influence clinical effectiveness and
safety. Our results could support these contributions. Like
efficacy and bioequivalence between the brand-name and
the generic drug, the results of this investigation suggest
that changes in the appearance of the drug may have re-
percussions for patient safety, especially in chronic dis-
eases, older patients and/or poly-medicated patients.
Reducing variability in the appearance (image of the drug
or similar) among chemically identical medicines could
help to discourage treatment discontinuation [31, 32].
The potential limitations of this investigation are those
inherent to its retrospective nature, such as disease
under-recording and potential variability between profes-
sionals and patients due to the investigation’s observational
design, the system of measurement used for the main vari-
ables, and the potential existence of a classification bias. In
this regard, any inaccuracy in diagnostic coding in the diag-
nosis of hypercholesterolemia, or the lack of a variable that
could affect the final results (socioeconomic status of pa-
tients, changes in the drug doses prescribed, changes in
form and presentation in the generics, etc.) should be con-
sidered as a limitation of the investigation. However, to our
understanding, the main deficiencies of the investigation
were as follows: a) the selection bias on the part of the
treating physician when starting a brand-name or generic
treatment, since this was not done randomly, as is typical
in a real-world situation, and b) the external validity of the
results (generalization), since the investigation was con-
ducted in institutions that provide healthcare services, with
similar organizational and clinical-management systems.
Also, this investigation was not able to analyze possible
side-effects of statins as these usually are not coded but in-
cluding as clinical notes. Consequently, the results of the
investigation should be interpreted with caution. Future ef-
forts should focus on replicating this investigation at other
healthcare institutions and on promoting intervention strat-
egies intended to promote patient adherence to the treat-
ments prescribed by their physicians.
Conclusions
In conclusion, meaningful and significantly lower levels of
treatment adherence and persistence were observed in pa-
tients with high LDL-cholesterol who first started therapy
with generic in comparison to brand-name statins in routine
medical practice in Spain. Also, compared with brand-name
statin therapy, this retrospective cost-consequences analysis
found that patients receiving generics were more unlikely to
reach LDL-c goals, showed increased probability of having a
major cardiovascular event and all-cause death at a higher
cost to payers.
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